Clinical trials: Neoplasm, Plasma Cell
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
The food and drug administration (FDA) has approved the use of Selinexor, an oral, first-in class, exportin 1 (XPO1) inhibitor, in combination with low-dose dexamethasone in patients with triple-refractory (disease refractory to…
- Trial name
- ESdRRMM (NCT05170789)
- Testing
- Elotuzumab, Selinexor, and Dexamethasone (ESd)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tulane University School of Medicine
Healthy
Predicting Progression of Developing Myeloma in a High-Risk Screened Population and General Population
We will seek consent from participants to use the data and biospecimens collected according study protocol to address additional research questions for MGUS, SMM, MM, and other conditions.
- Trial name
- NCT05837884
- Testing
- blood sampling
- Where
- 4 sites in Israel
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Multiple Myeloma
Etiology of Multiple Myeloma: A Case-Control Study
Objectives: The overall objective of this project is to identify risk factors associated with the development of multiple myeloma (MM) by integrating epidemiologic, clinical and molecular information.
- Trial name
- NCT00505999
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Melanoma, CNS Metastases
Collection of Cerebrospinal Fluid and Tumor Tissue in Subjects With Metastatic Melanoma and Controls
This study has two ultimate goals: 1. Understand how the original melanoma from the skin spreads to the CNS. In order to study this we need to collect (and compare) the original skin melanoma, the CNS melanoma, as well as any…
- Trial name
- NCT01312506
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Amyloidosis; Systemic, Amyloidosis Cardiac
Essen Amyloidosis Registry
The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis.
- Trial name
- EAR (NCT06887283)
- Where
- Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Acute Myeloid Leukemia, Multiple Myeloma
The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial
This multicenter, prospective, pilot randomized controlled trial aims to evaluate the feasibility and preliminary efficacy of a 16-week structured exercise program (SEP) in patients with hematologic malignancies, including acute…
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma
- Trial name
- Hematowellness (NCT07912684)
- Testing
- Structured Exercise Program (SEP)
- Where
- 3 sites in Italy
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Refractory Multiple Myeloma
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
1. Establish the MTD of Lintuzumab-Ac225 as monotherapy 2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR) 3. Confirm the safety profile of the treatment regimen 4.
- Trial name
- NCT02998047
- Testing
- Lintuzumab AC 225
- Where
- 5 sites in United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Actinium Pharmaceuticals
Lung Cancer, Breast Cancer
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches.
- Conditions
- Lung Cancer, Breast Cancer, Colorectal Cancer, Thyroid Cancer
- Trial name
- NCT06363123
- Where
- 4 sites in China
- Volunteers
- 2,700 people, healthy volunteers welcome
- Sponsor
- Beijing Friendship Hospital
Monoclonal Gammopathy of Undetermined Significance
MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition.
- Trial name
- MAGIC (NCT06472830)
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Plasma Cell Myeloma
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Primary Objectives: Safety run-in Part: To confirm the recommended dose of isatuximab when combined with lenalidomide and dexamethasone in participants with high-risk smoldering multiple myeloma (SMM) Randomized Phase 3 Part: To…
- Trial name
- NCT04270409
- Testing
- Isatuximab SAR650984, Lenalidomide, Dexamethasone
- Where
- 105 sites in United States, Australia and 22 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Sanofi
Systemic Amyloidosis
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic…
- Trial name
- NCT05951816
- Testing
- 99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Tennessee Graduate School of Medicine
Multiple Myeloma, Refractory
Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Immunotherapy has shown promise in the treatment of hematological malignancies, including multiple myeloma. One approach is CAR-NK cell therapy, which involves genetically modifying natural killer (NK) cells to target specific…
- Trial name
- NCT06242249
- Testing
- Anti-BCMA CAR-NK
- Where
- Iran
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
Multiple Myeloma, Low-Grade Lymphoma
64Cu-LLP2A for Imaging Hematologic Malignancies
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part…
- Conditions
- Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06636175
- Testing
- 64Cu-LLP2A, PET/CT
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Plasma Cell Disorders, Multiple Myeloma (MM)
GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.
- Trial name
- NCT07660939
- Testing
- GPRC5D-Targeted PET/CT Imaging
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Peking University First Hospital
Multiple Myeloma
Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma
The presence of minimal residual disease (MRD) is an important prognostic factor for multiple myeloma, while M-protein is a widely accepted biomarker used for multiple myeloma (MM) diagnose.
- Trial name
- NCT05536700
- Where
- China
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Blood Cancers, Blood Cancer
Rutgers University Study of the Genetics of Blood Cancers
The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online and a saliva sample through the mail, sequence DNA, and conduct…
- Conditions
- Blood Cancers, Blood Cancer, Leukemia, Lymphoma
- Trial name
- NCT07714044
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Pheochromocytoma, Obstructive Sleep Apnea
Metanephrines in Obstructive Sleep Apnoea
Although most patients have essential (unexplained) hypertension, some patients have a treatable underlying condition. One such condition is phaeochromocytoma, a tumour that produces excessive stress hormones.
- Conditions
- Pheochromocytoma, Obstructive Sleep Apnea, Catecholamine; Secretion
- Trial name
- NCT05053685
- Testing
- Measurement of Urine and plasma metanephrines
- Where
- Singapore
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Changi General Hospital
Multiple Myeloma
Amplification of Zinc Finger Protein 217 Gene in Multiple Myeloma
Multiple myeloma (MM) is blood disorder characterized by the detection of a monoclonal paraprotein in serum or urine, which is often associated with the presence of clonal plasma cells (PCs) mainly in the bone marrow (BM) .The…
- Trial name
- NCT04212858
- Testing
- zinc-finger protein 217 gene
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Multiple Myeloma, Multiple Myeloma Progression
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and…
- Conditions
- Multiple Myeloma, Multiple Myeloma Progression, Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
- Trial name
- NCT06644625
- Testing
- Blood draw for the laboratory assessment
- Where
- United States
- Volunteers
- 1,665 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences